# A Study Investigating Long-term Treatment With Spesolimab in People With a Skin Disease Called Hidradenitis Suppurativa Who Completed a Previous Clinical Trial

> **NCT04876391** · PHASE2 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 45 (actual)

## Conditions studied

- Hidradenitis Suppurativa

## Interventions

- **DRUG:** Spesolimab 1200 mg
- **DRUG:** Spesolimab 600 mg
- **DRUG:** Placebo matching 600 mg Spesolimab
- **DRUG:** Placebo matching 1200 mg Spesolimab

## Key facts

- **NCT ID:** NCT04876391
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-08-24
- **Primary completion:** 2024-04-26
- **Final completion:** 2024-04-26
- **Target enrollment:** 45 (ACTUAL)
- **Last updated:** 2025-11-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04876391

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04876391, "A Study Investigating Long-term Treatment With Spesolimab in People With a Skin Disease Called Hidradenitis Suppurativa Who Completed a Previous Clinical Trial". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04876391. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*